Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

Introduction
1. Study Objective
2. Scope of the report
3. Market Taxonomy
Study Assumptions and Abbreviations
1. Research Methodology
2. Secondary Research
3. Primary Research
4. SPSS Approach
5. Data Triangulation
Executive Summary
Global Industry Overview
1. Market Overview
2. Regional Synopsis
3. Industry Supply Chain Analysis
4. DROT
  1. Driver
  2. Restraint
  3. Opportunities
  4. Trends
5. Government Regulation: How they would Aid the Business?
6. Competitive Landscape
  1. AstraZeneca PLC
  2. Eli Lilly & Company
  3. Galmed Pharmaceuticals Ltd.
  4. GENFIT S.A.
  5. Novo Nordisk A/S
  6. Novartis AG
  7. PFIZER INC.
  8. Siemens Healthineers AG
  9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
  10. Zydus Lifesciences Limited
7. SWOT Analysis
8. Comparative Analysis Of The Current Technologies
9. Company Share in The Market
10. Analysis of Strategic Initiatives Adopted by Key Players
11. Drug Type Analysis
12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
13. Patent Analysis
14. Recent Developments
15. Industry Risk Assessment
Global Outlook and Projections
1. Global Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
  3. Year-on-Year Growth Forecast (%)
2. Global Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
3. Regional Synopsis (USD Million), 2024-2037
  1. North America, Value (USD Million)
  2. Europe, Value (USD Million)
  3. Asia Pacific, Value (USD Million)
  4. Latin America, Value (USD Million)
  5. Middle East and Africa, Value (USD Million)
Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
North America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. U.S.
    2. Canada
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Europe Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. NORDIC
    7. Russia
    8. Rest of Europe
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Asia Pacific Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. China
    2. Japan
    3. India
    4. Australia
    5. South Korea
    6. Vietnam
    7. Thailand
    8. Singapore
    9. Malaysia
    10. Rest of Asia Pacific
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Latin America Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Middle East & Africa Market
1. Overview
  1. Market Value (USD Million), Current and Future Projections, 2024-2037
  2. Increment $ Opportunity Assessment, 2024-2037
2. Segmentation (USD Million), 2024-2037, By
  1. Drug Type, Value (USD Million)
    1. Vitamin E and Pioglitazone
    2. Obeticholic Acid (OCA)
    3. Lanifibranor
    4. Semaglutide
    5. Resmetirom
    6. Aramchol
    7. Cenicriviroc
    8. Others
  2. End user, Value (USD Million)
    1. Hospital Pharmacies
    2. Retail and Specialty Pharmacies
    3. Others
  3. Country Level Analysis, Value (USD Million)
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
Global Economic Scenario
1. World Economic Outlook
About Research Nester
1. Our Global Clientele
2. We Serve Clients Across World

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc, Others)

Vitamin E and Pioglitazone segment is anticipated to account for more than 28.7% non-alcoholic steatohepatitis therapeutics and diagnostics market share by the end of 2037. This growth is attributed to their established efficacy in symptomatic alleviation of NASH and liver fibrosis reduction. Both therapies are considered cost-effective for their established clinical outcomes, which is boosting their adoption among healthcare providers. In May 2022, Pfizer Inc. announced that the FDA granted Fast Track designation to its investigational combination therapy for NASH with liver fibrosis, ervogastat (DGAT2 inhibitor) and clesacostat (ACC inhibitor). Such developments play a significant role in driving the demand for this drug type to fulfill unmet needs in the management of NASH.

End user (Hospital Pharmacies, Retail and Specialty Pharmacies, Others)

By 2037, retail and specialty pharmacies segment is projected to hold more than 49.2% non-alcoholic steatohepatitis therapeutics and diagnostics market share, driven by expanding access to advanced therapeutics. For such pharmacies, increasing access to innovative treatments has underlined their growing importance in the healthcare ecosystem. For example, the launch of Rezdiffra by Madrigal Pharmaceuticals in March 2024 further marked the retail and specialty pharmacies segment as a key player in delivering innovative therapies to patients. The specialty pharmacy is anticipated to garner rapid sales revenue as it provides tailored support and timely delivery for complex medications. Furthermore, their strategic positioning increases patient adherence to therapies and optimizes overall patient outcomes, which in turn drives the growth of the overall market.

Our in-depth analysis of the global non-alcoholic steatohepatitis therapeutics and diagnostics market includes the following segments:

Drug Type	Vitamin E and Pioglitazone Obeticholic Acid (OCA) Lanifibranor Semaglutide Resmetirom Aramchol Cenicriviroc Others
End user	Hospital Pharmacies Retail and Specialty Pharmacies Others

Frequently Asked Questions (FAQ)

In 2024, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics was USD 4.6 billion.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market size was USD 4.6 billion in 2024 and is projected to reach USD 117 billion by the end of 2037, expanding at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics will be valued at USD 5.9 billion.

Key players in the market are AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc among others.

The retail and specialty pharmacies segment is anticipated to lead the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

North America is anticipated to offer lucrative prospects to companies in the non-alcoholic steatohepatitis (Nash) therapeutics and diagnostics market during the forecast period.

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Browse Key Market Insights with Data Illustration:

Frequently Asked Questions (FAQ)

Subscribe to Our Newsletters

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Analysis

Browse Key Market Insights with Data Illustration:

Frequently Asked Questions (FAQ)

How big is the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics industry?

What is the outlook for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market?

Who are the major players dominating the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics landscape?

Which segment will capture the significant market share for non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics by 2037?

Which region will provide more opportunities for the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics business in the coming years?